HACKENSACK MERIDIAN HEALTH
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 2016-01-01
- Employees
- -
- Market Cap
- -
A Study of Daratumumab With Pomalidomide, Dexamethasone, and All-Transretinoic Acid in Patients With Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2021-01-07
- Last Posted Date
- 2025-02-25
- Lead Sponsor
- Hackensack Meridian Health
- Target Recruit Count
- 1
- Registration Number
- NCT04700176
- Locations
- 🇺🇸
John Theurer Cancer Center, Hackensack, New Jersey, United States
A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2020-12-10
- Last Posted Date
- 2025-02-25
- Lead Sponsor
- Hackensack Meridian Health
- Target Recruit Count
- 96
- Registration Number
- NCT04661137
- Locations
- 🇺🇸
John Theurer Cancer Center, Hackensack, New Jersey, United States
🇺🇸Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States
Variability in Transcranial Doppler Technique in Neuro-Critical Care Patients
- Conditions
- Cerebral AneurysmSubarachnoid Hemorrhage, AneurysmalStrokeAneurysmal Subarachnoid HemorrhageCerebral IschemiaVasospasm, Cerebral
- Interventions
- Diagnostic Test: Transcranial Doppler
- First Posted Date
- 2020-10-12
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- Hackensack Meridian Health
- Target Recruit Count
- 3
- Registration Number
- NCT04583163
- Locations
- 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
Expanded Access to Convalescent Plasma for Treatment of COVID-19
- Conditions
- COVID-19
- First Posted Date
- 2020-07-15
- Last Posted Date
- 2022-10-12
- Lead Sponsor
- Hackensack Meridian Health
- Registration Number
- NCT04472572
- Locations
- 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
Convalescent Plasma as Treatment for Subjects With Early COVID-19 Infection
- Conditions
- COVID-19
- Interventions
- Other: Best Supportive CareBiological: Convalescent Plasma
- First Posted Date
- 2020-07-02
- Last Posted Date
- 2023-10-10
- Lead Sponsor
- Hackensack Meridian Health
- Target Recruit Count
- 21
- Registration Number
- NCT04456413
- Locations
- 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
A Prospective "Universal" Observational Database for COVID-19
- Conditions
- COVID-19
- First Posted Date
- 2020-04-15
- Last Posted Date
- 2022-05-12
- Lead Sponsor
- Hackensack Meridian Health
- Target Recruit Count
- 4496
- Registration Number
- NCT04347993
- Locations
- 🇺🇸
Hackensack Meridian Health - John Theurer Cancer Center, Hackensack, New Jersey, United States
Hydroxychloroquine as Chemoprevention for COVID-19 for High Risk Healthcare Workers
- First Posted Date
- 2020-04-14
- Last Posted Date
- 2021-05-12
- Lead Sponsor
- Hackensack Meridian Health
- Target Recruit Count
- 48
- Registration Number
- NCT04345653
- Locations
- 🇺🇸
Hackensack Meridian Health - JFK Medical Center, Edison, New Jersey, United States
Convalescent Plasma as Treatment for Hospitalized Subjects With COVID-19 Infection
- Conditions
- COVID-19
- Interventions
- Biological: Convalescent Plasma
- First Posted Date
- 2020-04-13
- Last Posted Date
- 2023-09-18
- Lead Sponsor
- Hackensack Meridian Health
- Target Recruit Count
- 52
- Registration Number
- NCT04343755
- Locations
- 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
AMNIOX CORD Study - Radical Prostatectomy With and Without Cryopreserved Umbilical Cord Allograft
- Conditions
- Prostate Cancer
- Interventions
- Procedure: Robot-Assisted Radical ProstatectomyBiological: Cryopreserved Umbilical Cord Allograft
- First Posted Date
- 2020-02-10
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Hackensack Meridian Health
- Target Recruit Count
- 100
- Registration Number
- NCT04263025
- Locations
- 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- Drug: Granulocyte Colony-Stimulating Factor
- First Posted Date
- 2019-04-10
- Last Posted Date
- 2025-04-06
- Lead Sponsor
- Hackensack Meridian Health
- Target Recruit Count
- 18
- Registration Number
- NCT03909412
- Locations
- 🇺🇸
Hackensack Meridian Health - John Theurer Cancer Center, Hackensack, New Jersey, United States